Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Friday

Gyre Therapeutics (NASDAQ:GYRE) is anticipated to release its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to post earnings of ($0.15) per share and revenue of $28.40 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The firm had revenue of $29.11 million during the quarter, compared to the consensus estimate of $26.49 million. Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%. On average, analysts expect Gyre Therapeutics to post ($0.61) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Gyre Therapeutics Stock Performance

NASDAQ:GYRE opened at $4.43 on Thursday. Gyre Therapeutics has a 52 week low of $4.26 and a 52 week high of $9.14. The firm has a 50-day moving average price of $6.60 and a two-hundred day moving average price of $6.94. The firm has a market cap of $494.21 million, a price-to-earnings ratio of -21.10 and a beta of 2.14.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on GYRE shares. Wall Street Zen lowered Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Friday, August 7th. Finally, Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 6th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce”.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.